Potential Patchwork Of Local Drug Take-Back Programs Poses Problem For OTC Firms
This article was originally published in The Pink Sheet Daily
Executive Summary
Consumer products group backs litigation challenging drug take-back requirements to help stave off a patchwork of similar programs. Consumer education requires “a long-term commitment and won't be cheap,” but the OTC industry “can push back against more onerous mandates, says CHPA chief Scott Melville.
You may also be interested in...
States’ Cosmetic Ingredient Legislation Also Touching Drugs Gets CHPA's Highlight Treatment
“Lawmakers are not distinguishing between a cosmetic drug and a cosmetic that has no drug application at all,” says Carlos Gutierrez, CHPA’s state legislature lobby chief. Issues important to consumer health products industry can be found in unlikely places, he also tells HBW Insight.
State Officials Urging Rx Pseudoephedrine Face Strong Lobby
Officials from Mississippi, Missouri, Oregon and South Carolina and the National Narcotics Officers Associations Coalition testifying before a House subcommittee call for moving all PSE products to prescription status.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.